ProCE Banner Activity

BREEZE-AD5 Study Results: Efficacy and Safety of Baricitinib in Patients With Moderate to Severe Atopic Dermatitis

Slideset Download
Conference Coverage
Significantly improved skin inflammation, pain, itch, sleep, and quality-of-life outcomes in patients with moderate to severe AD treated with baricitinib vs placebo.

Released: August 11, 2020

Expiration: August 10, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

This educational activity is supported by educational grants from

AbbVie Inc.

Pfizer, Inc.